Ablacon, Inc., a Wheat Ridge, CO-based company developing an advanced mapping system to guide the treatment of atrial fibrillation (AFib), closed a $21.5m Series A financing round.
The round was led by Ajax Health.
The company will use the funding to advance its technology pipeline and finance clinical trials.
As part of the investment, Ajax Health CEO, Duke Rohlen will join Ablacon as Chairman and CEO.
The company leverages a novel algorithm that uses artificial intelligence (AI) to analyze and visualize the flow of action potentials, or Electrographic Flow, within the heart in order to identify sources and drivers of AFib, the most common cardiac arrhythmia worldwide.
The map of the Electrographic Flow can help to guide physicians in targeted catheter ablation therapy.
The technology obtained a CE Mark in 2018.